Peltopepimut-s is under clinical development by ISA Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Peltopepimut-s’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Peltopepimut-s overview
Peltopepimut-s (ISA-101) is under development for the treatment of human Papillomavirus (HPV)-16 associated cancers including oropharyngeal squamous cell carcinoma (OPSCC), cervical, vulvar vaginal, anal, head and neck squamous cell carcinoma and penile cancer. It is administered subcutaneously or intradermally. ISA101 consists of 13 synthetic long peptides (25-35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus. The vaccine candidate is developed based on proprietary SLP (Synthetic Long Peptide) concept. SLP concept is based on the use of synthetic long peptides for vaccination.
ISA Pharmaceuticals overview
ISA Pharmaceuticals is a developer of synthetic therapeutic vaccines for the treatment of cancer and persistent viral infections. The company’s pipeline products include ISA101, an immunotherapeutic vaccine for cervical cancer, MyISA, a personalized immunotherapy based on neoantigens to eradicate cancer; ISA203, preferentially expressed antigen in melanoma for treating different types of cancers; and ISA204 for the treatment of hepatitis B. It also develops synthetic long peptides technology used in the applications of viral and non-viral targets and provides multiple products for persistent virus infections. The company also provides amplivant technology, which is based on a proprietary and synthetic toll-like receptor agonist and is used in new generation immunotherapeutics for treating various diseases. ISA Pharmaceuticals is headquartered in Leiden, the Netherlands.
For a complete picture of Peltopepimut-s’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
